Arrowhead Pharmaceuticals (ARWR) News Today $16.29 +0.55 (+3.49%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tema Etfs LLC Takes $1.16 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Tema Etfs LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 61,503 shares of the biotechnology company's stock, valued at apprMay 20 at 6:16 AM | marketbeat.comDimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Dimensional Fund Advisors LP reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 70.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,666 shares of the biotechnology comMay 19 at 3:06 AM | marketbeat.comAnalysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $42.13May 19 at 1:47 AM | americanbankingnews.comSphera Funds Management LTD. Purchases New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Sphera Funds Management LTD. purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 197,550 shares of the biotechnology company's stock, valued at approximately $3,714,000.May 18 at 6:55 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six haveMay 18 at 2:22 AM | marketbeat.comB. Riley Has Positive Estimate for ARWR Q3 EarningsMay 17, 2025 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Increased to Hold at StockNews.comMay 17, 2025 | americanbankingnews.comQ3 Earnings Forecast for ARWR Issued By Leerink PartnrsMay 16, 2025 | americanbankingnews.comArrowhead Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesMay 15, 2025 | tipranks.comARWR: Multiple Value Drivers for Long-Term Growth…May 15, 2025 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings BeatArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings BeatMay 15, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)Chardan Capital restated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday.May 15, 2025 | marketbeat.comHudson Bay Capital Management LP Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Hudson Bay Capital Management LP reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,000 shareMay 15, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up Following Better-Than-Expected EarningsMay 15, 2025 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Quarterly Earnings ResultsArrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81.May 14, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call TranscriptMay 14, 2025 | msn.comIntegral Health Asset Management LLC Invests $5.17 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Integral Health Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 275,000 shares of the biotechnology company's stockMay 14, 2025 | marketbeat.comCitigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00May 14, 2025 | americanbankingnews.comArrowhead Shares Rise After 2Q Earnings BeatMay 13, 2025 | marketwatch.comArrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...May 13, 2025 | finance.yahoo.comNorthern Trust Corp Has $27.91 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Northern Trust Corp increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 11.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,484,419 shares of the biotechnology company'sMay 13, 2025 | marketbeat.comArrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter ResultsMay 13, 2025 | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comBalyasny Asset Management L.P. Has $7.01 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Balyasny Asset Management L.P. lifted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 266.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 372,749 shares of the biotechnology company's stockMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Buys Shares of 628,800 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Farallon Capital Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 628,800 shares of the bMay 11, 2025 | marketbeat.comBrevan Howard Capital Management LP Raises Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Brevan Howard Capital Management LP grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 232.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,556 shares of theMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 34,633 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Raymond James Financial Inc. purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,633 shareMay 10, 2025 | marketbeat.comVoya Investment Management LLC Has $1.01 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Voya Investment Management LLC trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownMay 9, 2025 | marketbeat.comArrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Earnings on ThursdayArrowhead Pharmaceuticals (NASDAQ:ARWR) will be releasing its Q2 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-arrowhead-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Increases Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Schonfeld Strategic Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 632,214 shares of the biotechnology coMay 3, 2025 | marketbeat.comMarshall Wace LLP Acquires New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Marshall Wace LLP acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 86,633 shares of the biotechnology company's stock, valued at approximately $1,629,000. MarMay 1, 2025 | marketbeat.comArrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter ResultsApril 30, 2025 | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Aquatic Capital Management LLCAquatic Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 80.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,394 shares of the biotechnApril 30, 2025 | marketbeat.comTower Research Capital LLC TRC Has $710,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Tower Research Capital LLC TRC boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 314.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,792 shares of the biotechnoApril 30, 2025 | marketbeat.comWells Fargo & Company MN Buys 18,933 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Wells Fargo & Company MN boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,886 shares of thApril 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Trims Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)T. Rowe Price Investment Management Inc. lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 29.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,507,296 shaApril 29, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Invesco Ltd.Invesco Ltd. lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 27.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 176,235 shares of the biotechnology company's stock after selling 66,April 29, 2025 | marketbeat.comBarclays PLC Buys 35,950 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Barclays PLC increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,560 shares of the biotApril 28, 2025 | marketbeat.comDark Forest Capital Management LP Purchases 78,078 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Dark Forest Capital Management LP boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172April 25, 2025 | marketbeat.comSlate Path Capital LP Purchases 347,000 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Slate Path Capital LP lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 7.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,232,000 shares ofApril 24, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Up 8.2% - What's Next?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.2% - What's Next?April 23, 2025 | marketbeat.comArrowhead Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 7,512 put options on the stock. This represents an increase of approximately 1,016% compared to the typical daily volume of 673 put options.April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys 2,222,223 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Avoro Capital Advisors LLC raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 25.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 11,111,111 shares of the biotechnology company's stock after buying an additional 2,April 23, 2025 | marketbeat.comCapital International Investors Sells 129,641 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Capital International Investors trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 50.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 126,230 shares of the biotechnology compaApril 23, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by BrokeragesShares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rApril 22, 2025 | marketbeat.comAltium Capital Management LLC Lowers Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Altium Capital Management LLC cut its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 35.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230,257 shares of the biotechnolApril 20, 2025 | marketbeat.comExecutive reshuffles: CAT, LMT, and APAApril 19, 2025 | msn.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. trimmed its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 41.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,289 shares of the biotechnApril 19, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 9.2% - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 9.2% - Here's WhyApril 18, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Cut by Fmr LLCFmr LLC decreased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,101,083 shares of the biotechnology companyApril 18, 2025 | marketbeat.com Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.800.65▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼347▲ARWR Articles Average Week Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Revolution Medicines News Elanco Animal Health News Blueprint Medicines News BridgeBio Pharma News Verona Pharma News Telix Pharmaceuticals Limited American Depositary Shares News Grifols News TG Therapeutics News Axsome Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
